Search

Your search keyword '"Brueckmann M"' showing total 319 results

Search Constraints

Start Over You searched for: Author "Brueckmann M" Remove constraint Author: "Brueckmann M"
319 results on '"Brueckmann M"'

Search Results

1. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

3. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

6. Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial

7. Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions

8. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

9. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

10. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

11. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

12. Cardiovascular and renal outcomes with empagliflozin in heart failure

14. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results from the EMPEROR-Reduced Trial

15. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial

16. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

17. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced

18. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced

19. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

20. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

21. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

25. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

26. Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

27. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

28. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

29. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

39. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

42. Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)

43. Design of the Effect of EMPaglifozin on ExeRcise ability and HF-symptoms, In patients with chronic heArt faiLure (EMPERIAL) trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction

46. PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

47. The potential role and rationale for treatment of heart failure with sodium–glucose co-transporter 2 inhibitors

50. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study

Catalog

Books, media, physical & digital resources